Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study

IntroductionThe treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatinib (an antiangiogenic agent) for patients with r/r...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Yanfei Liu, Yuqin Song, Shubo Zuo, Xian Zhang, Hui Liu, Jingwen Wang, Jingbo Wang, Yongjing Tang, Wen Zheng, Zhitao Ying, Lingyan Ping, Chen Zhang, Meng Wu, Jun Zhu, Yan Xie
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2023-04-01
Σειρά:	Frontiers in Immunology
Θέματα:	peripheral T-cell lymphoma PD-1 inhibitor apatinib immunotherapy camrelizumab
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1128172/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!